Selegiline and rasagiline, selective monoamine oxidase-B (MAO-B) inhibitors, have been hypothesized to exert a neuroprotective effect in PD by way of reducing physiologic stress associated with MAO-B oxidation of dopamine. Along with improvement in motor functions, several small, uncontrolled studies have found selegiline to be associated with improved global cognitive functioning, P300 latencies, and/or memory in patients with PD (137-140). In contrast, selegiline was reported not to significantly impact cognition in a large sample of untreated patients with early PD (141). The potential cognitive effects of rasagiline in PD patients have not been evaluated.
Was this article helpful?